The use of targeted LNP/mRNA technology to generate functional, transient CAR T cells and treat cardiac injury in vivo

Abstract

Rurik et al. [1] published in Science provide results from an elegant proof-of-concept study that modified messenger RNA (mRNA) encapsulated in targeted lipid nanoparticles (LNPs) can be delivered intravenously to produce functional engineered T cells in vivo . Specifically, they generated transient anti-fibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified mRNA in CD5 T cell-targeted LNPs.